Summit Therapeutics

Latest news

• Summit Therapeutics Inc. plans Datroway Phase III trial (opens in a new tab)

  Mugglehead Investment Magazine · Oct 2, 2026

• Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types (opens in a new tab)

  Investing News Network · Oct 2, 2026

• AstraZeneca and Daiichi Sankyo Partner with Summit Therapeutics to Study Datopotamab Deruxtecan and Ivonescimab (opens in a new tab)

  Oncodaily · Oct 2, 2026

• AstraZeneca, Daiichi Sankyo and Summit Therapeutics Plan Datroway–Ivonescimab Combination Trials (opens in a new tab)

  Yahoo Finance UK · Oct 2, 2026

• AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (opens in a new tab)

  Reuters · Oct 2, 2026

• AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo (opens in a new tab)

  Seeking Alpha · Oct 2, 2026

• AstraZeneca & Daiichi Sankyo announce clinical collaboration with Summit Therapeutics (opens in a new tab)

  TradingView · Oct 2, 2026

• Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway (opens in a new tab)

  Business Wire · Oct 2, 2026

• AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types (opens in a new tab)

  AstraZeneca · Oct 2, 2026

• Summit Therapeutics Is Maintained at Equal-Weight by Barclays (opens in a new tab)

  Moomoo · Oct 1, 2026

• What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership? (opens in a new tab)

  Yahoo Finance · Oct 1, 2026

• Summit Therapeutics Price Target Raised to $20.00/Share From $18.00 by Barclays (opens in a new tab)

  Moomoo · Oct 1, 2026

• Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Raises Target Price to $20 (opens in a new tab)

  Moomoo · Oct 1, 2026

• Summit Therapeutics Stock Climbs Wednesday: What's Happening? (opens in a new tab)

  TradingView · Sep 30, 2026

• AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets (opens in a new tab)

  24/7 Wall St. · Sep 30, 2026

• Leerink Partners Sticks to Its Hold Rating for Summit Therapeutics (SMMT) (opens in a new tab)

  The Globe and Mail · Sep 30, 2026

• H.C. Wainwright reiterates Summit Therapeutics stock rating as Neutral (opens in a new tab)

  Investing.com · Sep 30, 2026

• Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT) (opens in a new tab)

  The Globe and Mail · Sep 30, 2026

• AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll (opens in a new tab)

  BioSpace · Sep 30, 2026

• Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal (opens in a new tab)

  Investing.com · Sep 30, 2026

• AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics (opens in a new tab)

  Oncodaily · Sep 30, 2026

• AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up (opens in a new tab)

  Reuters · Sep 30, 2026

• AstraZeneca Backing Could Change The Case For Summit Therapeutics Stock (opens in a new tab)

  Simply Wall Street · Sep 29, 2026

• AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug (opens in a new tab)

  medcitynews.com · Sep 29, 2026

• AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says (opens in a new tab)

  Yahoo Finance · Sep 29, 2026

• Summit Therapeutics Rises as AstraZeneca Backs Ivonescimab With $2 Billion Investment (opens in a new tab)

  Quiver Quantitative · Sep 29, 2026

• Summit Therapeutics: Stronger Balance Sheet Helps, But It Does Not De-Risk Ivonescimab (opens in a new tab)

  Seeking Alpha · Sep 29, 2026

• AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology (opens in a new tab)

  Yahoo Finance · Sep 29, 2026

• Summit Shares Jump on $2B Strategic Investment From AstraZeneca (opens in a new tab)

  Yahoo Finance · Sep 29, 2026

• AstraZeneca Makes $2B Equity Investment in Summit Therapeutics (opens in a new tab)

  Contract Pharma · Sep 29, 2026